QCM Cayman’s Alaunos Therapeutics TCRT Stock Holding History

QCM Cayman’s Portfolio TCRT Stock Details TCRT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-75	Closed	-$12K	–	131
2021 Q4	$12K	Buy	+75	New	+$16.5K	0.07%	72

Other funds holding TCRT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return

DCM

Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

QCM Cayman's TCRT Position: Q1 2022 in Review

QCM Cayman sold out of Alaunos Therapeutics (TCRT) in Q1 2022, closing a stake of 75 shares — an estimated $12K sold.

QCM Cayman first reported a position in TCRT in Q4 2021 and held it in 1 quarter. The position peaked at $12K in Q4 2021. 148 funds tracked by Wall St. Rank hold TCRT as of Q1 2022.

QCM Cayman reported no remaining Alaunos Therapeutics position as of Q1 2022 after selling out during the quarter.
QCM Cayman sold 75 Alaunos Therapeutics shares in Q1 2022, an estimated $12K.
QCM Cayman first reported a position in Alaunos Therapeutics in Q4 2021 and held it in 1 quarter.
QCM Cayman's Alaunos Therapeutics position peaked at $12K in Q4 2021.
148 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q1 2022.

Based on QCM Cayman's 13F filing for Q1 2022, filed 6 May 2022.